Johnson & Johnson (JNJ)
Johnson & Johnson's OTTAVA Robotic Surgery System Targets Long-Term Growth
Johnson & Johnson NYSE: JNJ outlined its commercialization plans for the OTTAVA robotic surgical system after receiving U.S. Food and Drug Administration De Novo authorization, positioning the table-integrated platform as a long-term growth initiative in surgical robotics.
3 Dividend Stocks to Buy Before August Ends and Hold Forever
August has a habit of humbling investors. The VIX sits at 17.09, well off the March 2026 peak of 31.05, but the pattern is familiar: quiet summer tape, thin liquidity, and a single headline that can send correlations to one.
Johnson & Johnson (JNJ) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Johnson & Johnson Comes to Strategic Agreement with Sail Biomedicines
Under the agreement, Johnson & Johnson would make total initial payments of $785 million, and has the exclusive option to acquire Sail for $2.58 billion.
Johnson & Johnson offers $5.5 billion to settle remaining lawsuits over talc products linked to cancer
Johnson & Johnson has agreed to pay $5.5 billion to tie up remaining lawsuits that claim its talc products caused ovarian cancer.
Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits
Johnson & Johnson says it will pay an estimated $5.5 billion to settle about 76,000 lawsuits alleging its baby powder and talc caused ovarian cancer.
Johnson & Johnson proposes $5.5B settlement to resolve remaining talc litigation
Johnson & Johnson (NYSE:JNJ) has reached an agreement to resolve tens of thousands of lawsuits in the US alleging that its talc-based products, including its baby powder, caused ovarian cancer, with the company committing up to $5.5 billion to settle the remaining claims. The proposed resolution would bring an end to a long-running legal battle that has involved around 76,000 ovarian talc claims and weighed on the healthcare company for more than a decade.
Johnson & Johnson Stock Hits Record High on $5.5 Billion Settlement
Johnson & Johnson (NYSE:JNJ) was last seen up 2.4% at $272.31, and earlier hit a record high of $274.90, after the healthcare giant agreed to pay $5.5 billion to settle roughly 76,000 remaining U.S. lawsuits alleging its talc products caused ovarian cancer.
J&J offers $5.5bn to settle baby powder lawsuits
Johnson & Johnson (J&J) has offered to pay $5.5bn (£4.13bn) to resolve tens of thousands of lawsuits in the US alleging its talcum powder caused ovarian cancer.
ETFs to Buy Post JNJ's Q2 Earnings Beat & Bullish 2026 Outlook
Johnson & Johnson's Q2 beat and strong pharma momentum are raising interest in healthcare ETFs with sizable exposure to the company.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Johnson & Johnson's robotic surgery device gets US FDA marketing authorization
Johnson & Johnson said on Wednesday the U.S. Food and Drug Administration had granted marketing authorization for its robotic surgery device, clearing the way for the healthcare conglomerate to enter the soft-tissue robotic surgery market.
